A previous study reported that first‐generation EGFR‐TKIs were less effective for EGFR‐mutated squamous cell carcinoma than for adenocarcinoma, with an objective response rate of 31.6% and median progression‐free survival (PFS) of 3.08 months [9]. Here, EGFR is linked to adenocarcinoma.